Do you get really excited about working with the latest technological advances in the scientific field - and you are highly skilled in a range of methods and technologies to produce recombinant proteins?
Please keep reading!
At LenioBio GmbH, everything we do begins with our mission - to provide our customers with disruptive solutions to address their challenges easier, quicker, cheaper, better and safer.
Our ALiCE technology scales with the pharmaceutical R&D process, from discovery to clinical trials/product testing and finally, to GMP-grade production, in the form of an end-to-end integrated production platform.
LenioBio aims to unlock the full potential of ALiCE and will enable protein drugs to be brought to market faster and at lower cost.
About this job
To expand our lab-team in Aachen, which will soon move to Düsseldorf, we are looking for a talented Senior Bioprocess Scientist who gets excited about working with the latest bio-processing techniques.
As our dream candidate you are a champion in design and scaling from a lab environment to a fully integrated industrial platform, where data is instantly integrated, accessible and ready for scientific discovery and commercial production according to customer needs.
In this position you will build your international and fast-growing team with a focus to develop innovative and sustainable process concepts for industrial scale of recombinant protein production.
We are looking for people that want to bring the best, learn from the best, and create the best. That doesn’t mean you scored 180 on an IQ test. That means you are expert in your craft because you love what you do, you know you can get better, and you are constantly looking for the boundary of possibility.
This job will suit you best if you
What we offer
Who we are
LenioBio is a biotech company that develops and markets a novel and proprietary protein production platform, ALiCE®, which enables protein-based therapeutics to become more accessible and affordable. LenioBio was founded in 2016 in Germany to broadly commercialize the ALiCE® platform, originally developed by DowDuPont and the Fraunhofer Institute IME.
In August 2019, LenioBio closed its Series A investment round with private investors, and won a grant from the European Commission under the Horizon 2020 program/SME-2.
We aim to make them easy to remember, aspire to, and act on.
Have we triggered your interest? Then we are looking forward to your application in English*.
Do you have any questions up front? Please feel free to contact Ricarda at: +49 151 29504548.
*Applications through recruiters will not be considered.